Stonepine Capital Management, LLC Revance Therapeutics, Inc. Transaction History
Stonepine Capital Management, LLC
- $124 Billion
- Q4 2024
A detailed history of Stonepine Capital Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Stonepine Capital Management, LLC holds 23,264 shares of RVNC stock, worth $59,788. This represents 0.06% of its overall portfolio holdings.
Number of Shares
23,264
Previous 820,000
97.16%
Holding current value
$59,788
Previous $4.26 Billion
98.34%
% of portfolio
0.06%
Previous 2.69%
Shares
4 transactions
Others Institutions Holding RVNC
# of Institutions
208Shares Held
80.8MCall Options Held
2.22MPut Options Held
5.48M-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA5.94MShares$15.3 Million9.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$14.5 Million0.0% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I05.1MShares$13.1 Million0.78% of portfolio
-
Fil LTD Hamilton, D04.2MShares$10.8 Million0.01% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...